• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:顾丽,张君,苏燕.人催乳素受体拮抗剂G129R-hPRL在乳腺肿瘤治疗中的研究进展[J].中国现代应用药学,2011,28(1):30-34.
GU Li,ZHANG Jun,SU Yan.Advances in the Research of Human Prolactin Receptor Antagonists G129R-hPRL in Breast Cancer Therapy[J].Chin J Mod Appl Pharm(中国现代应用药学),2011,28(1):30-34.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2787次   下载 2870 本文二维码信息
码上扫一扫!
分享到: 微信 更多
人催乳素受体拮抗剂G129R-hPRL在乳腺肿瘤治疗中的研究进展
顾丽1, 张君2, 苏燕2
1.内蒙古科技大学包头医学院,a.病原生物学教研室,内蒙古 包头 014060;2.生物化学与分子生物学教研室,内蒙古 包头 014060
摘要:
目的 介绍特异性人催乳素(PRL)受体拮抗剂G129R-hPRL在乳腺肿瘤治疗中的研究进展。方法 查阅近年来国内外相关文献进行总结和归纳,对G129R-hPRL的功能、作用机制、优缺点、改进措施以及在乳腺肿瘤治疗中的应用和今后的发展方向进行综述。结果 G129R-hPRL通过竞争性拮抗内源性PRL的作用进而抑制乳腺癌细胞增殖,介导癌细胞凋亡,从而发挥其抗肿瘤效应。以G129R-hPRL为基础的多功能融合蛋白、以及与其他抗肿瘤成分联合应用显示出更强的肿瘤抑制效力。结论 G129R-hPRL有望成为一种治疗以及预防乳腺癌的理想药物。
关键词:  催乳素  催乳素受体拮抗剂  G129R-hPRL  乳腺肿瘤
DOI:
分类号:
基金项目:内蒙古自治区自然科学基金项目(200711020913)
Advances in the Research of Human Prolactin Receptor Antagonists G129R-hPRL in Breast Cancer Therapy
GU Li1, ZHANG Jun2, SU Yan2
1.Baotou Medical College, Inner Mongolia University of Science and Technology, a.Department of Pathogenic Organism, Baotou 014060, China;2.Department of Biochemistry Andmolecular Biology, Baotou 014060, China
Abstract:
OBJECTIVE To introduce the progress of specific human prolactin receptor antagonist G129R-hPRL in breast cancer therapy research. METHODS Review the function, mechanism, advantages and disadvantages, improvements, the application and the prospect of the prolactin receptor antagonist G129R-hPRL in therapy of breast tumor through searching and summarizing relevant literatures. RESULTS G129R-hPRL can inhibit proliferation, mediate apoptosis of breast cancer cell and play the role of anti-breast cancer by competitively antagonize endogenous prolactin. G129R-hPRL-based multi-functional fusion protein, as well as combination G129R-hPRL with other anti-tumor component also shows a stronger tumor suppressor effect. CONCLUSION G129R-hPRL is expected to be an ideal drug in treatment and prevention of breast cancer.
Key words:  prolactin  prolactin receptor antagonist  G129R-hPRL  breast tumor
扫一扫关注本刊微信